PATENT CLAIM ANALYSIS

Application Number: 15895252
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-10
Patent Classification: ["546", "268100"]

Abstract:
Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.

Claim (Index 93):
The method of  claim 92 , wherein R 11  is H; m is 0; and n is 1.

Metadata:
- Claim Count in Document: 40.0
- Percentile: 88.0
- Lexical Diversity: 1.67105
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14780788', '15091128', '14357699', '15162237', '14357701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7699361207195974
- 35 USC 102 Novelty (BERT): 0.515750968128717
- Combined Prediction Score: 0.7445176054605094
- Mean Citation Score: 281.6044399999999
- Max Citation Score: 312.2115
- Similarity Product: 273.4559946515858

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test